WELL Health Technologies Corp
TSX:WELL

Watchlist Manager
WELL Health Technologies Corp Logo
WELL Health Technologies Corp
TSX:WELL
Watchlist
Price: 4.01 CAD -1.47% Market Closed
Market Cap: 1B CAD
Section:
 

Relative Value

The Relative Value of one WELL stock under the Base Case scenario is 10.92 CAD. Compared to the current market price of 4.01 CAD, WELL Health Technologies Corp is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

WELL Relative Value
Base Case
10.92 CAD
Undervaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
96
vs Industry
57
Median 3Y
1.3
Median 5Y
1.6
Industry
2.3
Forward
0.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
30
Median 3Y
-9.1
Median 5Y
-23.8
Industry
22.4
Forward
9.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
35
Median 3Y
13.4
Median 5Y
13.9
Industry
14.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
15
Median 3Y
12.5
Median 5Y
12.3
Industry
21.5
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
71
vs Industry
50
Median 3Y
1.3
Median 5Y
1.5
Industry
2.2
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
96
vs Industry
52
Median 3Y
1.7
Median 5Y
2
Industry
2.5
Forward
1.1
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
95
vs Industry
52
Median 3Y
3.7
Median 5Y
4
Industry
5.1
More Details
16.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.5
vs History
36
vs Industry
24
Median 3Y
15.7
Median 5Y
15.3
Industry
12
Forward
7.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
11
Median 3Y
36.7
Median 5Y
32.5
Industry
17.1
Forward
16.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
17.8
Median 5Y
18.5
Industry
14.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
29
Median 3Y
17.1
Median 5Y
19.4
Industry
18.8
More Details
0.8
EV/IC
EV/IC
Enterprise Value to IC
0.8
vs History
87
vs Industry
55
Median 3Y
1
Median 5Y
1
Industry
1.8
More Details

Multiples Across Competitors

WELL Competitors Multiples
WELL Health Technologies Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
WELL Health Technologies Corp
TSX:WELL
1B CAD 0.8 -23.5 16.5 -1 197.1
US
CVS Health Corp
NYSE:CVS
100.9B USD 0.3 215.1 14.1 14.1
US
Cigna Corp
NYSE:CI
73.2B USD 0.3 11.9 7.7 9.8
US
Cigna Group
XMUN:CGN
61.5B EUR 0.3 11.8 7.6 9.7
DE
Fresenius SE & Co KGaA
XETRA:FRE
26.8B EUR 1.2 23.4 10.3 15.6
DE
Fresenius Medical Care AG
XMUN:FME
23.2B EUR 1.2 32.3 10.2 21.8
US
Laboratory Corporation of America Holdings
NYSE:LH
21.9B USD 1.6 25.6 13.9 19.4
US
Quest Diagnostics Inc
NYSE:DGX
20.3B USD 1.9 21 11.6 15.7
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.6B EUR 0.6 16.2 6.4 13.6
US
Guardant Health Inc
NASDAQ:GH
12.8B USD 14.1 -32 -33.8 -30.7
US
Hims & Hers Health Inc
NYSE:HIMS
8.5B USD 3.8 63.3 50.5 66.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
WELL Health Technologies Corp
TSX:WELL
Average EV/EBIT: 20.7
Negative Multiple: -1 197.1 		N/A N/A
US
CVS Health Corp
NYSE:CVS
14.1
18%
0.8
US
Cigna Corp
NYSE:CI
9.8
4%
2.4
US
C
Cigna Group
XMUN:CGN
9.7
4%
2.4
DE
Fresenius SE & Co KGaA
XETRA:FRE
15.6
20%
0.8
DE
Fresenius Medical Care AG
XMUN:FME
21.8
25%
0.9
US
Laboratory Corporation of America Holdings
NYSE:LH
19.4
27%
0.7
US
Quest Diagnostics Inc
NYSE:DGX
15.7
11%
1.4
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
13.6
25%
0.5
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -30.7 N/A N/A
US
Hims & Hers Health Inc
NYSE:HIMS
66.8
49%
1.4

See Also

Summary
WELL intrinsic value, competitors valuation, and company profile.
DCF Valuation
WELL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
WELL stock valuation using valuation multiples.
Wall Street Estimates
WELL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
WELL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.